LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, announces that its board of directors (the “Board”) has received a preliminary non-binding proposal letter (the “Proposal Letter”), dated August 18, 2025, from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (collectively, “Oceanpine Capital”) to acquire all of the outstanding ordinary shares, par value US$0.0002 per share, of the Company (the “Ordinary Shares”) that are not currently owned by Oceanpine Capital in an all-cash transaction for US$0.86 per Ordinary Share (the “Proposed Transaction”).
Read the full article: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company //
Source: https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-company-302532192.html